ArticleIn vivo (Athens, Greece)
Impact of COVID-19 Vaccine Type on the Efficacy and Safety of Nivolumab in Patients With Metastatic Non-small-cell Lung Cancer: A Multicenter Study.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThe effect of COVID-19 vaccine type on the outcomes of therapy immune checkpoint inhibitors remains unclear, and concerns persist regarding whether mRNA-based vaccines may negatively impact treatment efficacy or increase immune-related toxicity. This study aimed to evaluate the association between COVID-19 vaccination type and the efficacy and safety of nivolumab in patients with metastatic non-small-cell lung cancer (NSCLC). PATIENTS AND
methodsWe retrospectively analyzed 138 patients with driver-negative metastatic NSCLC treated with second-line nivolumab. Patients were classified as receiving virion-based (Sinovac) only, mRNA-based only, or both types of vaccines. Treatment response, progression-free survival, objective response rate, clinical benefit rate clinical benefit rate and immune-related adverse events were compared.
resultsThe overall response and clinical benefit rates were similar across vaccination groups, with no significant differences observed (
conclusionIn patients with metastatic NSCLC receiving second-line nivolumab, the efficacy and safety profile of nivolumab did not differ according to the type of COVID-19 vaccine patients had received prior to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.